Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study - Zeng, Qing-Lei; Zhang, Hong-Xu; Zhang, Ji-Yuan; Huang, Shuo; Li, Wei-Zhe; Li, Guang-Ming; Pan, Ya-Jie; Feng, Ying-Hua; Li, Zhi-Qin; Zhang, Guo-Fan; Xu, Jiang-Hai; Lin, Wan-Bao; et al. (Clinical gastroenterology and hepatology, 2022)
Keywords: Adenine - adverse effects; Adult; Antiviral Agents - adverse effects; China; Chronic Hepatitis B; Cleft Lip - chemically induced; Cleft Lip - drug therapy; Cleft Palate - chemically induced; Cleft Palate - drug therapy; Effectiveness; Female; Gastroenterology and Hepatology; Hepatitis B - diagnosis; Hepatitis B Surface Antigens; Hepatitis B, Chronic - drug therapy; Humans; Infant, Newborn; Mother-to-Child Transmission; Pregnancy; Pregnant Women; Prospective Studies; Safety; Tenofovir - adverse effects; Tenofovir Alafenamide; Tenofovir Disoproxil Fumarate; China; anti-HBs; eGFR; Chronic Hepatitis B; Effectiveness; HBeAg; ALT; HBsAg; Mother-to-Child Transmission; LMP; Pregnancy; Tenofovir Alafenamide; TDF; TAF; Safety; CHB; MTCT; Tenofovir Disoproxil Fumarate; HBV; WHO; estimated glomerular filtration rate; hepatitis B virus; alanine aminotransferase; hepatitis B e antigen; World Health Organization; hepatitis B surface antigen; last menstrual period; anti-hepatitis B surface antibody